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Purpose: To report two patients with associated conditions in addition to cystic fibrosis.
Methods: We reviewed our database and report two patients with cystic fibrosis who had associated conditions. These patients also had novel
disease causing CFTR mutations on full gene sequence analysis.
Results: We identified 2 patients with novel disease causing cystic fibrosis transmembrane conductance regulator mutations that we report here. A
12-year-old female with cystic fibrosis, diagnosed at 18 months, had normal pulmonary function tests and chest X-ray. Her main cystic fibrosis-
related health issue was poor growth. Results of cystic fibrosis transmembrane conductance regulator DNA analysis showed deltaF508; L467P;
and 7T/9T. She was later diagnosed with Crohn's disease. An 11-year-old male with Rubinstein–Taybi syndrome, diagnosed with cystic fibrosis
at 2 years of age, had minimal findings on chest X-ray and pancreatic insufficiency. Results of his cystic fibrosis transmembrane conductance
regulator DNA analysis showed deltaF508; 4329delCT; and 7T/9T.
Conclusion: We report 2 patients with CF who had associated conditions and also had novel disease causing CFTR mutations. Associated
conditions may worsen the clinical manifestations of CF and complicate medical management.
© 2010 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Cystic fibrosis; Mutation; Genetics; Gene sequence analysis; Cystic fibrosis transmembrane conductance regulator; Associated conditions; Crohn's
disease; Rubinstein–Taybi syndrome1. Introduction
Cystic Fibrosis (CF) is among the most common lethal genetic
diseases affecting Caucasians in the United States. There are
approximately 30,000 children and adults with CF in the United
States [1]. Incidence varies by ethnic group (Caucasians: 1:3200;
1:9200HispanicAmericans; 1;10,900NativeAmericans; African
Americans: 1:15,000; and Asian Americans: 1:31,000) [2,3]. It
is caused by mutations in the cystic fibrosis transmembrane
conductance regulator (CFTR) gene, which encodes an important☆ Disclosure statement: Co-author Steven Keiles is Vice President, Director of
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doi:10.1016/j.jcf.2010.04.007chloride ion channel expressed in the lungs, pancreas, intestine
and other tissues [4,5].
Clinically, CF affects primarily the respiratory, digestive,
and reproductive systems. To date, more than 1500 mutations
and polymorphisms have been identified throughout the CFTR
gene, making the DNA diagnosis difficult [6]. Appropriate
identification of CFTR gene mutations is important as it helps in
confirming the clinical diagnosis, helps genetic counseling, and
allows for the option of accurate prenatal diagnosis.
Children with CF are as likely to suffer from other associated
conditions as those without CF. Systemic manifestations of
associated conditions like failure to thrive, or gastrointestinal
complaints may confound the clinical picture of CF and make
its management more complicated. We report two patients with
CF who had other associated conditions, and who, on genetic
testing had novel disease causing CFTR mutations.d by Elsevier B.V. All rights reserved.
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2.1. Genetic testing
All patient samples underwent testing using either the
Ambry Test®:508 First™ or the Ambry Test®:CF Amplified
(Ambry Genetics, Aliso Viejo, CA, USA) which covers all
CFTR exons (OMIM 602421), at least 20 bases 5′ and 3′ into
each intron, as well as select deep intronic mutations. The
Ambry Test®:508 First ™ begins with Ambry Genetics:CFTR
deltaF508 RFLP procedure for detection of only the deltaF508
mutation. If homozygous deltaF508 is not detected, the test
includes a full mutation scan of the CFTR gene by modified
temporal temperature gradient electrophoresis (mTTGE) fol-
lowed by dye terminator sense and anti-sense directions. If
indicated, deletion/duplication studies are performed using
multiplex ligation-dependent probe amplification (MLPA)
[MRC-Holland, Amsterdam, The Netherlands].
2.2. Sweat chloride testing
A sweat test using pilocarpine iontophoresis sweat stimulation
and quantitative sample analysis with a chloridometer was per-
formed. Sweat chloride concentrations greater than 59 mmol/L
are considered ‘positive’. The minimum requirement is 0.075 g of
sweat before any test is analyzed.
3. Results
3.1. Case 1
A 12-year-old African-American female was diagnosed with
cystic fibrosis at 18 months of age (sweat chloride 105.7 meq/L,
106.5 meq/L) after presenting to gastroenterology clinic with
failure to thrive. She has had fourteen lifetime hospitalizations;
four of them in the second year of life for malabsorption; two
hospitalizations were for respiratory complaints. Systems
involved included:1. Respiratory: She had only one pulmonary CF exacerbation,
at 4 years of age when she was admitted to the hospital with
increased cough and a new left lower lobe infiltrate. When
she is well, her pulmonary function test results are normal
(FEV1 of 2.06 L, 100% predicted) as is her chest X-ray.
Respiratory cultures grew non-mucoid Pseudomonas aeru-
ginosa once (9 years, 10 months of age) and she currently
grows methicillin resistant Staphylococcus aureus (MRSA)
from her sputum. She has also grown H.influenzae, H.
parainfluenzae, and H. parahemolyticus in addition to
normal flora. She had nasal polyps and endoscopic sinus
surgery with bilateral polypectomies at 9 years of age.
2. Gastrointestinal: Since infancy, her main CF related health
issues have been gastrointestinal complaints and poor
growth. She is pancreatic insufficient (fecal elastase was
significantly reduced at 14.6 µg/g of stool) and continues on
pancreatic enzyme supplements.3. Unrelated co-morbidity: She developed joint pains, and
rectal hemorrhage and was subsequently diagnosed with
Crohn's disease at 10 years, 7 months of age. She has been
receiving treatment for Crohn's disease and has been doing
well since. Most of her hospitalizations have been for
gastrointestinal complaints, which are thought to be related
to her Crohn's disease.
4. Nutrition: She was diagnosed secondary to failure-to-thrive
and nutrition has been a major problem for her. At present,
the patient is at the 17th percentile for BMI. She has a
gastrostomy tube which was inserted in the second year of
life. Her poor weight gain is believed to be mainly due to
Crohn's disease.
5. CF related diabetes: At 10 years, 6 months of age, she was
diagnosed with CF-related diabetes.
6. Genetic diagnosis: The results of CFTR DNA showed
deltaF508; L467P; 7T/9T. Her mother's CFTR DNA
showed L467P; Q250R, confirming that the patient's two
mutations are on different chromosomes, confirming the
diagnosis of cystic fibrosis. The mother is a compound
heterozygote and appears to be completely asymptomatic at
this time. Her sweat chloride test result was within normal
limits. This suggests that the Q250R, another novel variant
which has not been seen in over 25,000 patients tested at
Ambry (personal communication), is not disease causing or
is associated with mild CF disease that has not yet become
symptomatic.
Currently, she receives infliximab monthly for Crohn's
disease, insulin on a sliding scale, and carbohydrate counting
for diabetes control. She does her respiratory treatments regularly
using high frequency chest compression vest and alpha dornase.
3.2. Case 2
An eleven-year-old Caucasian male with Rubinstein–Taybi
syndrome was diagnosed with CF at 2 years, 4 months of age
(sweat chloride-107.6 meq/L, 0.25 gm of sweat; 104.6 meq/L,
0.45 gm of sweat) with presenting symptoms of failure to thrive
and diarrhea. Since diagnosis he has had eight hospitalizations,
one of which has been for a pulmonary exacerbation at age
2 years, 7 months; the others for gastrointestinal complaints,
including dehydration. Systems involved include:
1. Respiratory: He has minimal pulmonary symptoms and
receives antibiotic treatment only occasionally for upper
respiratory tract infections. His chest X-ray shows minimal
hyperexpansion and mildly increased peribronchial mark-
ings. His sputum cultures grew Pseudomonas aeruginosa
once when he was 2 years, 7 months of age and currently
grow Stenotrophomonas maltophilia and methicillin sensi-
tive Staphylococcus aureus. He has grown Streptococcus
pneumoniae in addition to normal respiratory flora; he is
unable to perform PFTs due to developmental delay that is
thought to be due to his genetic syndrome.
2. Gastrointestinal: He has pancreatic insufficiency [fecal fat
study – random 49% fat (normal b20%) at 2 years of age,
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also diagnosed with lactose intolerance based on a
therapeutic trial when he was 9 years, 6 months old, the
treatment of which resolved his longstanding complaint of
diarrhea.
3. Co-morbidity: He was diagnosed with Rubinstein–Taybi
syndrome following a genetics consultation made due to
persistent failure-to-thrive and developmental delay. This
syndrome occurs in an estimated 1 in 100,000 to 125,000
newborns and is characterized by short stature, moderate to
severe intellectual disability, distinctive facial features, and
broad thumbs and first toes [7]. Other features include eye
abnormalities, heart and kidney defects, dental problems,
and obesity. Failure-to-thrive is a rare presenting symptom of
Rubinstein–Taybi syndrome and may be associated with
life-threatening infections. The diagnosis in this patient was
made based on dysmorphic features, developmental delay,
and failure to thrive.
4. Nutrition: His major clinical problem has been failure to
thrive, which is thought to be at least partially related to his
syndrome. He is currently at 8th percentile of BMI.
5. Genetic testing: A full gene analysis revealed deltaF508;
4329delCT; 7T/9T. His mother has the 4329delTC mutation,
confirming that the patient is a compound heterozygote and
making the diagnosis of cystic fibrosis disease.
In summary, he has minimal pulmonary symptoms and
pancreatic insufficiency, with his gastrointestinal symptoms
well controlled on pancreatic enzyme replacement therapy. His
failure to thrive is attributed to his genetic syndrome.
4. Discussion
Both patients presented early with gastrointestinal and
nutritional complaints, which are most likely due to their
associated conditions. The novel mutations L467P variant and
the 4329delCT variant have not been reported in the literaturebut appear to be disease causing in our patients based on sweat
testing and the presence of pancreatic insufficiency. It is
difficult to confidently comment on the role of CF versus the
associated conditions in the morbidity of the patients; however,
patient #1 has done very well with no further hospitalizations
since the initiation of treatment for Crohn's disease, suggesting
that the latter was primarily responsible for her morbidity. As
seen in our patient, Crohn's disease can be very debilitating
especially in patients with CF, and early identification and
treatment will improve quality of life in these patients. It also
may worsen the prognosis in these children, given the
complications of Crohn's disease.
It is important to remember that patients with CF are as likely
as others to have co-morbid conditions that can be responsible
for or may worsen their presenting CF symptoms. A high index
of suspicion for early diagnosis and treatment will help in
reducing symptoms and improving quality of life in these
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